NCT03638167View on ClinicalTrials.gov

EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 19, 2019

Primary Completion Date

December 22, 2023

Study Completion Date

December 22, 2023

Conditions

Central Nervous System Tumor, PediatricGliomaEpendymomaMedulloblastomaGerm Cell TumorAtypical Teratoid/Rhabdoid TumorPrimitive Neuroectodermal TumorChoroid Plexus CarcinomaPineoblastoma

Interventions

BIOLOGICAL

EGFR806-specific chimeric antigen receptor (CAR) T cell

Autologous CD4+ and CD8+ T cells lentivirally transduced to express an EGFR806 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter

Trial Locations (1)

98105

Seattle Children's Hospital, Seattle

All Listed Sponsors

lead

Seattle Children's Hospital

OTHER

NCT03638167 - EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors | Biotech Hunter | Biotech Hunter